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Abstract: Melanoma accounts for only a small portion of skin cancer but it is associated 
with high mortality. Melanoma serum biomarkers that may aid early diagnosis or guide 
therapy  are  needed  clinically.  However,  studies  of  serum  biomarkers  have  often  been 
hampered by the serum interference that causes false readouts in immunological tests. Here 
we show that, after using a special buffer to eliminate the serum interference, IL-8 and 
cathepsin  B  levels  were  significantly  elevated  in  melanoma  patients  (p  <  0.05). 
More importantly,  the  combination  of  IL-8  and  cathepsin  B  were  also  studied  as  a 
prognosis marker for melanoma mortality. Our study provides a novel approach to examine 
serum biomarkers. 
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1. Introduction  
Melanoma is a malignancy that arises from melanocytes in the skin and eye. According to the 
American  Cancer  Society,  melanoma  of  skin  is  the  5th  most  common  cancer  in  the  USA  and 
accounted for 4–5% of newly diagnosed cancer cases in 2009. The incidence of this cancer has been 
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increasing for more than 30 years, and the number of melanoma cases worldwide is increasing faster 
than any other types of cancer [1]. Although melanoma only represents a very small portion of all skin 
cancers, it is responsible for the majority of skin cancer deaths. Early detection of melanoma has led to 
an increase of the 5-year relative survival rates from ~80% in 1975 to >90% in 1996 [2].  
Most  of  the  melanomas  retain  melanocytic  differentiation  markers  such  as  S-100,  Melan-A, 
tyrosinase,  tyrosinase  related  proteins  (TRPs),  Microphthalmia,  HMB-45,  and  so  forth  [3].  These 
markers  (except  for  S-100)  are  very  specific  and  are  used  clinically  to  confirm  melanocytic 
differentiation by immunohistochemical staining. The serum level of 5-s-cysteinyldopa (5-SCD), a 
pheomelanin precursor, has been reported to correlate with the progression of melanoma [4], although 
it is also elevated in some other patients with skin hyperpigmentation, such as patients with renal 
disease and subject to hemodialysis [5]. S100A has been studied as a biomarker to predict relapse and 
death. Immunohistochemical analysis indicates that certain subtypes, such as S100BB, are associated 
with increased risk of relapse [6]. Lower serum S100A1B and S100BB have also been associated with 
better survival. However, currently only serum lactate dehydrogenase (LDH) is clinically used as a 
biomarker for late stage melanoma as recommended by the American Joint Committee on Cancer 
tumor, node, metastasis staging system [7]. There is a clear unmet medical need to develop other 
melanoma serum biomarkers for disease progression. A large number of serum proteins have been 
screened in proteomic studies and novel approaches have been applied to study these proteins [8–10].  
We  previously  discovered  a  supersensitive  immune  detection  assay  to  analyze  low  abundant 
antigens in sera [11]. We have since studied several molecules, including cytokines and melanocyte 
specific antigens in the sera of patients with melanoma. To our surprise, detection of many of these 
proteins was not hampered by the sensitivity of the assay but by the serum interference that causes 
false  positive  signals.  The  culprit  for  the  serum  interference  was  the  presence  of  high  levels  of 
heterophilic  human  anti-animal  immunoglobulin  antibodies  (HAIA),  such  as  human  anti-mouse 
antibodies (HAMA),  in  certain populations of people  [12]. HAIA is  produced  by human  immune 
reaction  following  an  exposure  to  mice  or  other  animal  agents,  including  murine  monoclonal 
antibodies  associated  with  some  therapeutic  or  diagnostic  procedures  [13].  Some  human  
auto-antibodies, the most common of which is rheumatoid factor (RF), also bind to animal antibodies 
by cross reactivity. The prevalence of HAIA is varied in different reports (reviewed in [12]). In one 
study, human anti-bovine antibodies were detected in 99% of the donor serum samples [14]. 
Since HAIA represents a big interference for ELISA assays on serum samples, many approaches 
have been proposed to reduce the effect of these agents. Maher et al. reported that HAMA was no 
longer  an  issue  if  immunoglobulin-  free  fraction  of  serum  was  used  for  immunoassays  [13].  The 
strategy, however, was not practically sound considering the number of samples and the cost of the 
procedure. Mouse IgG derived blocking reagents, such as Immunoglobulin Inhibiting Reagent (IIR; 
Bioreclamation), Heterophilic Blocking Reagent (HBR; Scantibodies), Heteroblock (mixture of active 
and passive blocking reagents; Omega Biologicals), and MAB 33 (monoclonal IgG1) and Poly MAB 33 
(polymeric  monoclonal  IgG1/Fab;  Boehringer  Mannheim),  have  also  been  developed  for  HAMA 
positive samples, but the results varied [15]. A common practice in the immunoassay for a suspected 
sample is to use alternative detection antibodies of different species. Yu et al. reported false-positive 
detection of extremely high levels of the C-reactive protein (CRP) when goat-anti CRP antibody was 
used to test the serum from a subject who had no corresponding symptoms [16]. In this case, the Int. J. Mol. Sci. 2011, 12                       
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culprit was identified as the monoclonal IgM- paraprotein that had bind to the goat antibody. The use 
of chicken antibodies appears to avoid the HAMA interference in some assays [17,18].  
In  this  report,  we  have  examined  the  serum  concentrations  of  several  potential  melanoma 
biomarkers using an approach that eliminates the serum interference. Previously, elevated IL-8 level 
was associated with metastatic melanoma [19], and decrease of serum IL-8 levels were correlated with 
response to chemotherapy or immunochemotherapy [20]. In a proteomic analysis, elevated cathepsin B 
level was detected from the sera of mice carrying human melanoma xenografts [21]. Here, our studies 
indicate that the IL-8 level is significantly elevated in melanoma but not in breast cancer patients, 
while the Cathepsin B level is higher in both melanoma and breast cancer as compared with healthy 
subjects. Like LDH, the combination of IL-8 and Cathepsin B serum levels can be used to predict the 
medium term mortality (3–5 years) of melanoma patients. The potential implication of our observation 
is discussed.  
2. Results and Discussion  
2.1. Optimization of ELISA Assay 
During the course of studying serum biomarkers, we encountered problems with certain samples 
that suspiciously showed elevated levels for almost all the targets we tested. Two examples were 
shown in Figure 1 (left panel). Following the suggested conditions in commercially developed ELISA 
kit, we detected “high concentrations” of both IL-8 and Tyrosinase (Tyr) in the serum samples M38 
and M16. M38 was obtained from a melanoma patient but unexpectedly M16 was from a healthy 
volunteer. The sandwich ELISA used an unmodified capture antibody and a biotinylated detection 
antibody for each antigen. The tertiary antibody-antigen complex was detected by the biotin-binding 
streptavidin-HRP conjugate. To test whether the signal was antigen-specific, we designed a control 
assay using non-matching antibody sets, e.g., a MIA detection antibody paired with the Tyr capture 
Ab, or a VEGF detection Ab paired with the IL-8 capture Ab (Figure 1, the “non-specific” panel). The 
results  showed  strong  signals  in  both  samples,  indicating  that  previous  ELISA  readings  of  these 
samples under conventional conditions were erroneous and misleading. 
The  heterophilic  human  anti-animal  immunoglobulin  antibodies  (HAIA)  may  account  for  the 
misleading results in the ELISA assay [22]. If the serum samples containing HAIA recognizes the 
Fc region  of  the  capture  and  detection  antibody,  it  will  crosslink  these  two  antibodies,  leading  to  
false-positive signals in the absence of the true antigen. On the other hand, if the existing HAMA binds 
to the Fv regions of the capture or detection antibody, it will prevent the true antigen from binding to 
the detection or capture antibody, resulting in a false-negative signal. 
After  initial unsuccessful experience with  several commercial serum interference inhibitors, we 
have identified a buffer named MBB (Martell Biosystems, Inc.) that eliminates the false readings. 
HAIAs are generally less specific and have lower affinity towards the target. The MBB buffer is 
designed to prevent the weak interaction between HAIA and the target but not the strong interaction 
between capture/detection antibodies and specific antigens.  
In the “standard” ELISA, serum samples were diluted 1:10 with 1% BSA. When MBB buffer was 
used to dilute the serum samples, the non-specific binding, as revealed by the non-matching pairs of Int. J. Mol. Sci. 2011, 12                       
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antibodies, disappeared (Figure 1, right panels). The MBB buffer was thus applied to the ELISA to 
measure the specific binding to targets. Sample M16 from healthy volunteer was no longer positive for 
Tyr or IL8 in the presence of MBB. In contrast, the melanoma sample M38 was still positive for IL-8. 
Clearly, the readouts under the conventional conditions were influenced by the HAIA in the serum and 
did not reflect the true concentrations of these antigens. We believe the modified ELISA assay using 
MBB provides the true value for serum concentrations of target proteins. 
Figure 1. MBB reduces non-specific bindings in the ELISA assay. Serum samples NHS, 
M16, and M38 were diluted in either 1% BSA (left) or MBB buffer (right) for ELISA 
assay. For Tyrosinase (Tyr), antibody T9230 (US Biologicals) and biotinylated T311 were 
used as the capture antibody and the detection antibody, respectively. For IL-8, the IL-8 
Cytoset from Biosource was used. To show non-specific bindings, Tyr or IL-8 capture 
antibodies  were  used  but  biotinylated  anti-MIA  or  anti-VEGF  antibodies  were  used 
respectively as the detection antibodies. 
 
2.2. Analysis of Serum IL-8 
Using the MBB buffer to eliminate the serum interference, we have analyzed several serum markers 
that may associate with melanoma. First we studied IL-8, a cytokine secreted by melanoma cells. 
Serum  levels  of  IL-8  were  significantly  higher  in  melanoma  patients  (p  <  0.01)  (Figure  2).  The 
elevated IL-8 levels were independent of age (Table 1). A trend of higher IL-8 levels in later stages of 
melanoma was observed (Table 1) but the difference was not statistically different. In a study of a 
group of breast cancer patients, the average IL-8 levels in breast cancer was higher than that of control, 
but the difference was not statistically different. Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Comparison of serum cathepsin B, IL-8 and Tyrosinase in melanoma, breast 
cancer and healthy controls. 
   
 
Table 1. Comparison of serum IL-8 levels (pg/mL) by groups. 
   N  MEAN  SD  SE 
Melanoma         
Age         
<50  19  209.1  544.2  124.8 
50–59  16  40.5  56.9  14.2 
60–69  17  136.6  255.2  61.9 
≥70  15  161.5  305.3  78.8 
Stage         
II  4  20.8  17.6  8.8 
III  18  76.8  191.5  45.1 
IV  45  175.5  304.7  60.2 
Overall  67  139.8  347.7  42.5 
Breast Cancer         
Overall  24  76.7  210.3  43.9 
Control         
Overall  13  8.6  6.6  1.8 
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2.3. Analysis of Serum Cathepsin B 
Cathepsin B was found to be elevated in the sera of mice carrying human melanoma xenografts [21]. 
Cathepsin B is a lysosomal enzyme that is involved in cancer invasion and metastasis [23]. We thus 
examined if serum cathepsin B from melanoma patients can be used as a biomarker to predict the 
progress  of  the  disease.  Indeed,  significantly  elevated  levels  of  Cathepsin  B  (as  determined  by 
unpaired t test) were observed in melanoma patients. However, Cathepsin B levels were also elevated 
in breast cancer patients, indicating that cathepsin B is not unique to melanoma but may be associated 
with  general  tumor  progression.  Cathepsin  B  levels  were  also  independent  of  age  and  stages  of 
melanoma (Table 2). 
Table 2. Comparison of serum Cathepsin B levels (ng/mL) by groups. 
   N  MEAN  SD  SE 
Melanoma         
Age         
<50  19  22.7  8.6  2.0 
50–59  16  23.4  15.7  3.9 
60–69  17  34.5  38.8  9.4 
≥70  15  24.4  14.6  3.8 
Stage         
II  4  18.1  2.9  1.5 
III  18  23.6  11.3  2.7 
IV  45  28.0  26.5  4.0 
Overall  67  26.2  22.6  2.8 
Breast Cancer         
Overall  24  38.6  43.5  8.9 
Control         
Overall  13  15.8  8.1  2.2 
2.4. Analysis of Serum Tyrosinase 
Tyrosinase, a type I membrane protein and copper-containing enzyme, is involved in the production 
of melanin. Melanin biosynthesis requires the enzymatic activity of tyrosinase, which catalyzes the 
critical and rate limiting step of tyrosine hydroxylation [24]. Defects affecting tyrosinase activity result 
in various forms of albinism [25]. We examined the serum levels of tyrosinase. Despite detection of 
extremely high levels of tyrosinase in the serum of several melanoma patients, there was no difference 
in the average levels between melanoma and controls. Breast cancer samples also appeared to have 
baseline levels of tyrosinase. Our data indicate that serum tyrosinase is not an effective biomarker for 
melanoma or breast cancer. 
2.5. Analysis of Additional Cytokines 
Although in general melanoma patients have higher serum IL-8 and cathepsin B levels, neither of 
these two proteins is expected to serve as a single melanoma biomarker. For example, using 2 ×  SD 
above the average of the control group as the cut-off value, we determined that the sensitivity of serum Int. J. Mol. Sci. 2011, 12                       
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IL-8 for melanoma is just about 46%. The sensitivity of cathepsin is even lower. In addition, elevated 
levels of these proteins have been observed in other cancer patients, leading to lower specificity for 
both proteins as melanoma biomarkers. However, it is suggested that IL-8 and cathepsin B could be 
used together and incorporated into a melanoma biomarker panel. To study if additional serum proteins 
can also be used to characterize melanoma, we also performed multiplex ELISA assays in MBB buffer 
using the Milliplex cytokine/chemokine kit for 39 human target proteins (Millipore) for sera from 
11 melanoma patients. We found that nine cytokines/chemokines showed statistically higher levels in 
melanoma patients compared to controls (Table 3). 
Table 3. Cytokine and chemokine expression in melanoma patients and healthy controls. 
Cytokines  Melanoma  Control  p 
gm-CSF  21.9 ±  4.55  8.86 ±  3.2  <0.05 
INF-  297 ±  30.7  150 ±  16.9  <0.01 
IL1-  4.78 ±  0.93  0.64 ±  0.0  <0.01 
IL1-  4.87 ±  1.75  0.064 ±  0.0  <0.05 
IL-7  395 ±  119  6.72 ±  3.52  <0.01 
IL-8  1083 ±  417  7.8 ±  2.34  <0.05 
IP-10  985.3 ±  98.5  741.1 ±  14.29  <0.05 
MIP-1  199.7 ±  51.95  46.88 ±  15.60  <0.05 
TNF  25.9 ±  5.03  11.6 ±  3.14  <0.05 
2.6. Serum Biomarkers for Melanoma Specific Death 
Clinical follow up data were available on these patients for up to 3 years post serum collection. We 
noticed a higher mortality rate for patients who had extremely high levels of these circulating proteins: 
100% (2 out of 2) for cathepsin B, 66.7% (6 out of 9) for IL-8, and 75% (3 out of 4) for tyrosinase. To 
further study whether these serum markers may predict prognosis, melanoma patients were divided 
into  the  High  mortality  group  or  the  Low  mortality  groups  depending  on  their  status  during  the  
follow-up for 3 years. For all patients who suffered from melanoma-related death within 3 years after 
enrollment of the study, their serum samples collected at the beginning of the study were assigned to 
the High Mortality group. Samples from other subjects who survived for more than 3 years after 
enrollment of the study were allocated into the Low mortality group. Both groups consist of patients 
with diversified disease stages (II–IV). Some patients did not have measurable disease at the time of 
serum collection. The initial serum levels of investigated target proteins were compared between these 
two groups. The serum levels were considered elevated if they were above the cut-off value, which 
was determined using the average value of controls plus 2 standard deviation (average ±  2 ×  SD). 
Unexpectedly,  none  of  these  biomarkers  (IL-8,  Cathepsin  B,  or  tyrosinase)  can  be  used  as  an 
independent biomarker to differentiate the High and Low mortality groups (p > 0.05, data not shown). 
A modest increased of mortality was observed in patients with high IL-8 levels. The mortality was 
62.9%  in  patients  with  elevated  IL-8  levels,  and  48.7%  in  patients  with  normal  IL-8  levels.  
This resulted in a risk ratio of 1.29, with 95% confidence interval (CI) ranging from 0.86 to 1.95  
(p > 0.05). There was also a higher risk of mortality for patients with elevated cathepsin B levels  
(risk ratio = 1.38) but the difference was not statistically significant (Fisher’s exact test, p > 0.05).  Int. J. Mol. Sci. 2011, 12                       
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To investigate if the combination of IL-8 and Cathepsin B can be used for predicting mortality, we 
established a biomarker scoring system and assigned 1 score for a patient if he had elevated level of 
any of these two biomarkers. A patient received at most 2 scores when he had elevated levels for both 
IL-8 and Cathepsin B. Using such a scoring system, we were able to show that patients in the High 
mortality group had significantly higher scores (p < 0.05) (Figure 3).  
Figure 3. Biomarker scores can be used for the prognosis of melanoma. Serum samples 
from melanoma patients were tested for elevated levels of IL-8 and Cathepsin B. High 
mortality group: patients died within 3 years after enrollment of the study; Low mortality 
group: patients survived for more than 3 years after enrollment of the study. Patients were 
scored based on the initial serum levels of IL-8 and Cathepsin B. Patients receive 0 score 
for normal levels, 1 score for elevated levels of only one biomarker and 2 scores if both 
were elevated. Patients in the High mortality group showed significantly higher scores as 
judged by unpaired t test. Data were presented as mean ±  SEM. 
 
For  melanoma, Lactate dehydrogenase  (LDH) is  not  a  specific  marker but  has  been  used  as  a 
prognostic marker for metastasis [7]. We also retrospectively examined all the available LDH records 
for patients we have for this study. First we looked at the LDH levels at the time when the patients 
donated  their  serum  samples  for  the  study.  Patients  in  the  High  mortality  group  demonstrated 
significantly  higher  levels  of  LDH  than  those  in  the  Low  mortality  group  (674.1  ±   80.3  U/L  vs.  
471.2  ±   38.1  U/L,  p  =  0.04).  This  confirms  the  significance  of  LDH  as  a  prognosis  marker  for 
melanoma. Furthermore, we also examined the follow-up LDH value at 18 months after the initial 
visit, or the last available value if patients were deceased before 18 months. The Low mortality group 
showed significant reductions in LDH levels in the follow-up (paired t test, p < 0.0001), while the 
High mortality group experienced no detectable changes in the LDH levels (p = 0.76) (Figure 4). Our 
data indicated that the change of LDH could be used as a much better biomarker than the baseline level 
for the prognosis of melanoma related death.  
Unfortunately, we did not collect follow-up serum samples from these patients for the analysis of 
IL-8, Cathepsin B or Tyrosinase. It is not clear if melanoma patients experience changes in the serum 
of these proteins and if that change can be used as an accurate biomarker for prognosis.  Int. J. Mol. Sci. 2011, 12                       
 
 
1513 
Figure 4. LDH as a prognosis marker for melanoma. Records of LDH levels of patients at 
the time of serum sample donation as well as 18-months later (or the last available LDH 
record if the patient died before 18-months follow-up) were examined. Patients in the High 
mortality group had significantly higher levels of LDH than those in the Low mortality 
group. The Low mortality group also showed significant reductions in LDH levels in the 
follow-up  (paired  t  test,  p  <  0.001),  while  the  High  mortality  group  experienced  no 
detectable changes in the LDH levels. 
 
2.7. Discussion 
Despite the reports of a variety of serum proteins as potential biomarkers for the diagnosis and 
prognosis of melanoma, few can be confirmed in large scale studies. According to the joint committee 
of tumor staging, LDH is the only marker that can clinically help characterize melanoma. Although 
many factors may account for this, one issue that cannot be ignored is the false positives that inflate the 
variation of test results among already complex samples. As we have experienced in the study of 
biomarkers  using  immunological  approaches,  the  use  of  serum  proteins  as  biomarkers  have  been 
hampered  by  the  unpredictable  serum  interference  due  to  the  presence  of  human  anti-animal 
immunoglobulin antibodies (HAIA).  
We have shown that by using a special buffer to eliminate serum interferences, two serum proteins, 
IL-8 and Cathepsin B, were significantly elevated in melanoma patients. Although the analysis of 
breast cancer samples indicated that elevated IL-8, not Cathepsin B, was associated with melanoma, 
both proteins are not unique to melanoma. To our surprise, Tyrosinase, a melanocyte specific marker 
that  is  involved  in  pigment  synthesis  [24],  appears  to  maintain  a  normal  level  in  the  majority  of 
melanoma patients as compared to healthy or breast cancer patients. We also studied MIA, another 
melanocyte specific marker, and unexpected found that only a small number of melanoma patients 
have elevated serum levels (data not shown). Furthermore, using multiplex assay, we have identified 
additional cytokines/chemokines that have higher serum levels in melanoma.  
There are clear evidences that IL-8 is associated with melanoma progression. IL-8 is produced by 
melanoma cell lines and functions as an autocrine growth factor [26]. Elevated IL-8 levels have been 
observed in patients with metastatic melanoma [19]. Higher blood levels of IL-8 and IL-6 may be 
associated with the Brenner sign, which is an erythematous eruption in the vicinity of or distant from Int. J. Mol. Sci. 2011, 12                       
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the lesion in melanoma patients [27]. In a group of stage IV melanoma patients, decreased serum IL-8 
levels are found in patients with response to chemotherapy or immunochemotherapy [20]. By blocking 
IL-8, the anti-IL8 antibody (ABX-IL8) effectively reduced the growth of melanoma xenografts as well 
as metastasis of melanoma cells [28]. Due to the importance of its involvement in the development and 
metastasis  of  melanoma,  IL-8  has  been  studied  frequently  together  with  other  pro-inflammatory 
cytokines to identify potential clinical biomarkers for diagnosis and prognosis [29].  
Cathepsin B is a cysteine protease that has been found upregulated in aggressive human pancreatic 
endocrine  neoplasms  [23].  Secreted  active  cathepsin  B  was  detected  from  both  preneoplastic  and 
malignant cells [30]. Cathepsin B may play a role in the promoting of tumor cell invasiveness, as 
cathepsin B deficiency resulted in reduced tumor vascularity and invasion in mice [23]. Knocking 
down of cathepsin B by RNAi also led to comprised glioma cell invasion and angiogenesis both in 
vitro and in vivo [31]. 
In our study, serum cathepsin B levels were elevated in both melanoma and breast cancer patients. 
Based on these data, it is suggested that cathepsin B might be relevant to the development of a broad 
range of tumor, possibly contributing to the tumor cell migration and metastasis due to its protease 
function. Interestingly, IL-8 and cathepsin B, the two proteins we have been focusing on in our study, 
appeared to have somehow linked functions. In a study of endothelial cell migration mediated by IL-8, 
cathepsin B was found to be critical for IL-8 induced transactivation of EGFR [32]. 
More importantly, our study suggests that serum IL-8 and cathepsin B levels can potentially be used 
as prognostic markers for melanoma. In fact, the combination of IL-8 and cathepsin B into a scoring 
system  has  been  shown  to  differentiate  deceased  patients  from  those  who  survived  the  3  year  
follow-up. However, we understand that additional studies are required to further confirm the use of 
IL-8/Cathepsin B as prognosis markers. In this initial study, patients are not controlled for treatments. 
We are planning to examine the changes of IL-8 and Cathepsin B levels over the course of controlled 
treatments. It will be clinically useful if IL-8/Cathepsin B can be used to predict the treatment response 
in patients so unresponsive patients may consider other treatment options as early as possible. We 
expect that further study could verify if any additional serum proteins, such as those identified in our 
multiplex study, can be incorporated into the scoring system to establish the melanoma biomarker 
panel for both diagnosis and prognosis.  
3. Experimental Section  
3.1. Patients 
Melanoma  patients (stages II–IV, n = 67) were consecutive patients diagnosed with  melanoma 
through the oncology clinic at the University of Pennsylvania. Patients did not all have measurable 
disease at the time they donated serum samples for the study. In addition, we also studied sera from 
patients with breast cancers (n = 24) to test whether the changes were specific for melanoma. Control 
participants were healthy volunteers. All participants were recruited according to a protocol approved 
by the institutional review board (IRB) and informed that this study is purely investigational in nature 
and that results of individual tests will not be made available to them.  Int. J. Mol. Sci. 2011, 12                       
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3.2. ELISA Assay with MBB Buffer 
ELISA kit for IL-8 (Biosource, Catalog # CHC1303) and Cathepsin B (R&D Systems, Catalog 
# DCATB0)  were  purchased.  For  ELISA,  the  capture  antibodies  (anti-IL-8,  Biosource  clone 
893A6G8), anti-Tyr (Santa Cruz, # 9230), and anti- cathepsin B (R&D, Clone155714) were coated in  
carbonate-bicarbonate  coating  buffer  (pH  9.6,  1  g/mL,  50  L)  to  a  96-well  plate  for  overnight 
incubation at 4 ° C. After wash with PBST, the plate was blocked with 1% casein or 5% BSA for 1 h at 
22 ° C. Protein standard and serum samples were diluted in the blocking buffer containing BSA or 
MBB (Martell Biosystem) and incubated in the blocked plate (50 L per well) for a 1-h incubation at 
22 ° C. Diluted biotinylated detection antibody (50 L, 180 ng/mL, with MBB) was added to each well 
and incubated for 1 h. Detection antibodies we used were: anti-IL8: clone 790A28G2 (Biosource), 
anti-Tyr: Clone T311 (Neomarkers). Streptavidin-conjugated HRP was used as the secondary antibody 
to detect the antigen-antibody complex. The Streptavidin-HRP step was skipped for Cathepsin B as the 
detection antibody from the kit was already HRP-conjugated. The plate was washed three times with 
PBST (0.1% Tween 20 in PBS) in-between incubations. In addition, the cathepsin B plate was washed 
three  times  with  PBST  containing  1  M  Urea  before  the  incubation  with  the  detection  antibody. 
Following  six  washes  with  PBST  to  remove  excess  detection  antibodies,  100  mL  of  tetramethyl 
benzidine (TMB) substrate (0.1 mg/mL, 0.05 M phosphate-citrate buffer, pH 5.0) was incubated in 
each well at 22 ° C. The reaction was stopped within 15–30 min with 50 L of 2 M H2SO4, and the data 
was collected at 450 nm (absorbance filter) using the SpectraFluor reader (Tecan). 
3.3. Statistical Methods  
The data were analyzed using GraphPad Prism (version 4.0C; GraphPad Software, La Jolla, CA). 
Unpaired t test was performed to determine if there was statistical significance between groups. Paired 
t-test was only used to compare the initial and follow-up LDH values from the same patient. All 
reported p values are two-sided. p values less than 0.05 were considered statistically significant.  
4. Conclusions 
In summary, our study indicates that serum biomarker studies must be carefully designed to exclude 
the false influence from non-specific serum antibodies. We have shown that, after the elimination of 
serum  interference,  IL-8  and  cathepsin  B  were  significantly  elevated  in  melanoma.  Additional 
cytokines/chemokines were also identified as potential serum biomarkers to characterize melanoma. 
Our studies have provided a basis for the investigation of the change of serum biomarkers (e.g., IL-8 
and cathepsin B) as an approach to monitor patients for treatments. 
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